This metabolic disturbance stems from three key insulin resistance‐mediated pathological changes: (1) enhanced peripheral lipolysis and subsequent free fatty acid (FFA) overflow to the liver (Fabbrini et al. 2008); (2) activation of hepatic de novo lipogenesis via SREBP‐1c pathway (Postic and Girard 2008); and (3) impaired VLDL secretion capacity (Adiels et al. 2005). Here, SREBF1 is linked to Insulin resistance.